MannKind Corporation Overview
Pro stress-test →MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases. The company closed 2025 on a high note with the acquisition of scPharmaceuticals and record fourth-quarter revenue surpassing $100 million. With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation.
Strategic Profile
Pro stress-test →MannKind is renowned for developing and commercializing inhaled therapeutic products, with its flagship product being Afrezza (insulin human) Inhalation Powder. The addition of Furoscix strengthens the company's cardiometabolic franchise, while Afrezza and United Therapeutics-related revenues continue to deliver sustained growth. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Competitive Landscape
Pro stress-test →Limited awareness, slow market penetration, and rising competition from large pharma constrain growth despite strong trends favoring MannKind's inhaled therapies. Key competitors include Novo Nordisk and Eli Lilly in insulin/diabetes space, plus Janssen and Roche in pulmonary disease treatments. MannKind maintains strategic collaborations with United Therapeutics Corporation for Tyvaso DPI development and regulatory/commercial activities.
Industry Context
MannKind Corporation operates in Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment.
Key facts
Headquarters: Danbury, Connecticut and Westlake Village, California, United States · Revenue: $313.79M · Market cap: $1.71B